BUND FINANCE

BUND FINANCE › Stocks › RVMD

Revolution Medicines, Inc. (RVMD)

NASDAQ · Stock price, chart and technical analysis

US$159.82-2.87 (-1.76%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$162.69
OpenUS$162.35
Day rangeUS$158.41 – US$163.04
52-week rangeUS$69.50 – US$224.31
Market capUS$34.57B
Volume2.34M
50-day averageUS$192.71
200-day averageUS$160.55
Beta1.43

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$29.4MUS$35.4MUS$11.6MUS$0US$0
Net income−US$187.1M−US$248.7M−US$436.4M−US$600.1M−US$1.1B
EPS (diluted)-2.57-3.08-3.86-3.58-5.95
Gross margin100.0%100.0%100.0%——
Operating margin-639.7%-730.0%-4,207.1%——
Net margin-636.6%-703.0%-3,768.3%——
Free cash flow−US$153.7M−US$235.2M−US$358.3M−US$567.7M−US$913.7M
Total debtUS$66.6MUS$64.2MUS$87.9MUS$135.8MUS$158.7M
CashUS$108.5MUS$161.4MUS$696.1MUS$543.1MUS$383.7M

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E——27.1x
EV / EBITDA——16.5x
Operating margin-853.0%—3.6%
Net margin-946.8%—-0.0%
Debt / equity0.79—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Revolution Medicines, Inc.

SectorHealthcare
IndustryBiotechnology
CountryUS
CEOMark A. Goldsmith
Employees883
IPO date2020-02-13

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic ar…

www.revmed.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice